[1] |
.
[J]. Clinical Focus, 2012, 27(13): 1149-1150.
|
[2] |
.
[J]. CLINICAL FOCUS, 2007, 22(1): 44-0.
|
[3] |
.
[J]. CLINICAL FOCUS, 2006, 21(23): 1713-1714.
|
[4] |
.
[J]. CLINICAL FOCUS, 2006, 21(15): 1093-1094.
|
[5] |
.
[J]. CLINICAL FOCUS, 2004, 19(13): 755-756.
|
[6] |
.
Comparison of serum lipid levels with apolipoproteins in rheumatic heart disease and dilated cardiomyopathy
[J]. CLINICAL FOCUS, 2004, 19(5): 244-246.
|
[7] |
.
Time and dose-effect relationships of prostaglandin E1 on pulmonary hypertension caused by rheumatic heart disease
[J]. CLINICAL FOCUS, 2004, 19(1): 14-17.
|
[8] |
.
Clinical investigation on 518 cases with rheumatic heart disease
[J]. CLINICAL FOCUS, 2003, 18(19): 1096-1098.
|
[9] |
.
Risk factors of left atrial thrombus in patients with rheumatic valve disease
[J]. CLINICAL FOCUS, 2003, 18(5): 249-251.
|
[10] |
.
[J]. CLINICAL FOCUS, 2003, 18(1): 14-14.
|
[11] |
.
Percutaneous balloon mitral valvuloplasty for the patients with rheumatic mitral stenosis and left atrial thrombi
[J]. CLINICAL FOCUS, 2003, 18(1): 9-9.
|
[12] |
.
[J]. CLINICAL FOCUS, 2002, 17(22): 1322-1322.
|